The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment

Atherosclerosis Supplements

Volumn 2, Issue 4, 2002, Pages 19-25

  Stein, Evan ^a  

^a Metabolic and Atherosclerosis Research Center   (United States)

Author keywords

Aggressive cholesterol reduction; Goal attainment; Low density lipoprotein

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; COLESTYRAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; OUTCOMES RESEARCH; PATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT INDICATION; BLOOD; DRUG EFFECT; REVIEW; TREATMENT OUTCOME;

CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; TREATMENT OUTCOME;

EID: 1242318531     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(01)00020-4     Document Type: Conference Paper

References (20)

1. Keys A, editor. Coronary heart disease in seven countries. Circulation 1970;41(Suppl 1):1-211.
2. Verschuren W.M., Jacobs D.R., Bloemberg B.P., Kromhout D., Menotti A., Aravanis C., Blackburn H., Buzina R., Dontas A.S., Fidanza F., et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the Seven Countries Study. J. Am. Med. Assoc. 274:1995;131-136.
3. Assmann G., Cullen P., Schulte H. The Muster Heart Study (PROCAM): results of follow-up at 8 years. Eur. Heart J. 19:(Suppl. A):1998;A2-A11.
4. Wilson P.W., Anderson K.M., Castelli W.P. Twelve-year incidence of coronary heart disease in middle aged adults during the era of hypertensive therapy: the Framingham Offspring Study. Am. J. Med. 90:1991;11-16.
5. Chen Z., Peto R., Collins R., MacMahon S., Lu J., Li W. Serum cholesterol concentrations and coronary heart disease in population with low cholesterol concentrations. Br. Med. J. 303:1991;276-282.
6. Frederickson D.S., Gotto A.M., Levy R.I. Familial lipoprotein deficiency (Abetalipoproteinemia, Hypobetlipoproteinemia, and Tangier Disease). Stanbury J.B., Wyngaarder J.B., Frederickson D.S. The Metabolic Basis of Inherited Disease. 3rd :1972;512 McGraw-Hill, New York, NY.
7. Pedersen T.R. Aggressive lipid-lowering therapy: a clinical imperative. Eur. Heart J. 19:((Suppl. M)):1998;M15-M21.
8. Pedersen T.R., Kjekshus J., Olsson A.G., Cook T.J. 4S results support AHA guidelines to reduce LDL-cholesterol to less than 100 mg/dl in patients with CHD. Circulation. 96:((Suppl. I)):1997;717.
9. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
10. Pitt B., Waters D., Brown W.V., van Boven A.J., Schwartz L., Title L.M., Eisenberg D., Shurzinske L., McCormick L.S. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N. Engl. J. Med. 341:1999;70-76.
11. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 357:2001;577-581.
12. Knatterud G.L., Rosenberg Y., Campeau L., Geller N.L., Hunninghake D.B., Forman S.A., Forrester J.S., Gobel F.L., Herd J.A., Hickey A., Hoogwerf B.J., Terrin M.L., White C. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation. 102:2000;157-165.
13. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K, for the Second Joint Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-503.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
15. Olsson A.G., Pears J., McKellar J., Mizan J., Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am. J. Cardiol. 88:2001;504-508.
16. Paoletti R., Fahmy M., Mahla G., Mizan J., Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomised, double-blind study. J. Cardiovasc. Risk. 8:2001;383-390.
17. Davidson M., Ma P., Stein E., Gotto A.M., Raza A., Chitra R., Hutchinson H. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin vs. atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am. J. Cardiol. 89:2002;268-275.
18. Stein E, Strutt KL, Miller E, Southworth H. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2001;37(Suppl A):292A. Abstract 1261-176.
19. Stein E, Strutt KL, Miller E, Southworth H. Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2001;2:90-1. Abstract P176.
20. Pharmaprojects Web site. Available at: http://www.pjbpubs.com/scrip/fax. htm . Accessed April 24, 2001.